Elissa Prichep
1 post
Elissa spent the past 12 years launching specialty therapeutics and initiatives in the bio-pharmaceutical industry and developing economic policy in the public sector. She most recently lead patient strategy and digital innovation for biosimilar immunology products at Merck, brought their ground-breaking immunotherapy cancer treatment to market and developed their first 24/7 patient support program. Elissa earned her MBA as a Woodruff Fellow at Emory University and her B.A. from Cornell University.
mRNA Vaccines – Here’s Everything You Need To Know
In December 2020, the US FDA issued emergency use authorization for mRNA vaccines developed by Pfizer-BioNTech and Moderna,…
2021-09-06